Multimedialna platforma wiedzy medycznej Internetowa Księgarnia Medyczna Kalendarium Konferencji
Neurologia i Neurochirurgia Polska
MENU
Shortcuts Submit an article Guide for Authors Special collections Ahead Of Print Reviewers 2023

open access

Vol 55, No 2 (2021)
Review Article
Submitted: 2021-01-26
Accepted: 2021-02-22
Published online: 2021-04-02
View PDF Download PDF file
Get Citation

Botulinum toxin type-A preparations are not the same medications — clinical studies (Part 2)

Jarosław Sławek1, Andrzej Bogucki2, Marcin Bonikowski3, Halina Car4, Malgorzata Dec-Ćwiek5, Artur Drużdż6, Dariusz Koziorowski7, Iwona Sarzyńska-Długosz8, Monika Rudzińska9
DOI: 10.5603/PJNNS.a2021.0028
·
Pubmed: 33797748
·
Neurol Neurochir Pol 2021;55(2):141-157.
Affiliations
  1. Medical University of Gdansk, Poland, Gdansk, Poland
  2. Medical University of Lodz, Poland, Al. KOściuszki 4, 90-419 Lodz, Poland
  3. Mazovian Neuropsychiatry Center, Limited Liability Company Neuro Rehabilitation Department, Movement Analysis Lab. Zagórze n. Warsaw, Poland, Wiązowna, 05-462 Zagórze
  4. Department of Experimental Pharmacology, Medical University of Bialystok, ul. Waszyngtona 15A, 15-274 Białystok, Poland
  5. Jagiellonian University,Collegium Medicum, l. św. Anny 12,, 31-008 Kraków, Poland
  6. Department of Neurology, Municipal Hospital, Szwajcarska 3,, 61-285 Poznań, Poland
  7. Neurology Dpt., Medical University of Warsawa, Faculty of Health Sciences,, ul. Kondratowicza 8, 03-242 Warszawa, Poland
  8. 8. Second Department of Neurology, Neurorehabilitation Ward, Institute of Psychiatry and Neurology, Warsaw, Poland, ul. Sobieskiego 9, 02-957 Warszawa, Poland
  9. 9. Department of Neurology, Faculty of Medicine and Health Sciences. Andrzej Frycz Modrzewski Kraków University, ul. Gustawa Herlinga Grudzińskiego 1, 30-705 Kraków, Poland

open access

Vol 55, No 2 (2021)
REVIEW ARTICLES — LEADING TOPIC
Submitted: 2021-01-26
Accepted: 2021-02-22
Published online: 2021-04-02

Abstract

The growing number of Botulinum neurotoxin type A (BoNT/A) preparations on the market has resulted in a search for pharmacological, clinical and pharmacoeconomic differences. Patients are occasionally switched from one botulinum toxin formulation to another.

The aim of this paper was to review studies that have made direct comparisons of the three major BoNT/A preparations presently on the market: ona-, abo- and incobotulinumtoxinA. We also review the single medication Class I pivotal and occasionally Class II-IV studies, as well as recommendations and guidelines to show how effective doses have been adopted in well-established indications such as blepharospasm, hemifacial spasm, cervical dystonia and adult spasticity.

Neither direct head-to-head studies nor single medication studies between all preparations allow the formation of universal conversion ratios. All preparations should be treated as distinct medications with respect to their summary of product characteristics when used in everyday practice.

Abstract

The growing number of Botulinum neurotoxin type A (BoNT/A) preparations on the market has resulted in a search for pharmacological, clinical and pharmacoeconomic differences. Patients are occasionally switched from one botulinum toxin formulation to another.

The aim of this paper was to review studies that have made direct comparisons of the three major BoNT/A preparations presently on the market: ona-, abo- and incobotulinumtoxinA. We also review the single medication Class I pivotal and occasionally Class II-IV studies, as well as recommendations and guidelines to show how effective doses have been adopted in well-established indications such as blepharospasm, hemifacial spasm, cervical dystonia and adult spasticity.

Neither direct head-to-head studies nor single medication studies between all preparations allow the formation of universal conversion ratios. All preparations should be treated as distinct medications with respect to their summary of product characteristics when used in everyday practice.

Full Text:

View PDF Download PDF file
Get Citation

Keywords

botulinum toxin type A, cervical dystonia, blepharospasm, spasticity, hemifacial spasm

About this article
Title

Botulinum toxin type-A preparations are not the same medications — clinical studies (Part 2)

Journal

Neurologia i Neurochirurgia Polska

Issue

Vol 55, No 2 (2021)

Article type

Review Article

Pages

141-157

Published online

2021-04-02

Page views

1560

Article views/downloads

1614

DOI

10.5603/PJNNS.a2021.0028

Pubmed

33797748

Bibliographic record

Neurol Neurochir Pol 2021;55(2):141-157.

Keywords

botulinum toxin type A
cervical dystonia
blepharospasm
spasticity
hemifacial spasm

Authors

Jarosław Sławek
Andrzej Bogucki
Marcin Bonikowski
Halina Car
Malgorzata Dec-Ćwiek
Artur Drużdż
Dariusz Koziorowski
Iwona Sarzyńska-Długosz
Monika Rudzińska

References (80)
  1. Sławek J, Car H, Bonikowski M, et al. Are botulinum toxin type A preparations really the same medication? A comparison of three botulinum toxin A for variations in labelled neurological indications. Neurol Neurochir Pol. 2010; 44(1): 43–64.
    CrossRefPubMed
  2. Ferrari A, Manca M, Tugnoli V, et al. Pharmacological differences and clinical implications of various botulinum toxin preparations: a critical appraisal. Funct Neurol. 2018; 33(1): 7–18.
    CrossRefPubMed
  3. Car H, Bogucki A, et al. Botulinum toxin type-A preparations are not the same medications – basic science (Part 1) . Neurol Neurochir Pol . 2021; xxxxxxxxxxxxxxxx.
  4. Allergan, Ltd. BOTOX® 100 U. Summary of product characteristics [webpage on the Internet]. Surrey, UK: Datapharm Communications Ltd; 2013. http://www.medicines.org.uk/emc/medicine/112 (October 8, 2020).
  5. Dysport® (abobotulinumtoxinA) [prescribing information]. Boulogne-Billancourt: IpsenBiopharm Ltd; 2012. (October 8, 2020).
  6. XEOMIN (50/100/200) units powder for solution for injection –summary of product characteristics. https://www.medicines.ie/medicines/xeomin-50-100-200-units-powder-for-solution-for-injection-34858/spc#! (November 2019).
  7. Marion MH, Sheehy M, Sangla S, et al. Dose standardisation of botulinum toxin. J Neurol Neurosurg Psychiatry. 1995; 59(1): 102–103.
    CrossRefPubMed
  8. Sampaio C, Ferreira JJ, Simões F, et al. DYSBOT: a single-blind, randomized parallel study to determine whether any differences can be detected in the efficacy and tolerability of two formulations of botulinum toxin type A--Dysport and Botox--assuming a ratio of 4:1. Mov Disord. 1997; 12(6): 1013–1018.
    CrossRefPubMed
  9. Nüssgens Z, Roggenkämper P. Comparison of two botulinum-toxin preparations in the treatment of essential blepharospasm. Graefes Arch Clin Exp Ophthalmol. 1997; 235(4): 197–199.
    CrossRefPubMed
  10. Bihari K. Safety, effectiveness, and duration of effect of BOTOX after switching from Dysport for blepharospasm, cervical dystonia, and hemifacial spasm dystonia, and hemifacial spasm. Curr Med Res Opin. 2005; 21(3): 433–438.
    CrossRefPubMed
  11. Marchetti A, Magar R, Findley L, et al. Retrospective evaluation of the dose of Dysport and BOTOX in the management of cervical dystonia and blepharospasm: the REAL DOSE study. Mov Disord. 2005; 20(8): 937–944.
    CrossRefPubMed
  12. Bentivoglio AR, Ialongo T, Bove F, et al. Retrospective evaluation of the dose equivalence of Botox(®) and Dysport (®) in the management of blepharospasm and hemifacial spasm: a novel paradigm for a never ending story. Neurol Sci. 2012; 33(2): 261–267.
    CrossRefPubMed
  13. Dressler D. Routine use of Xeomin® in patients previously treated with Botox®: long term results. European Journal of Neurology. 2009; 16: 2–5.
    CrossRef
  14. Roggenkämper P, Jost WH, Bihari K, et al. NT 201 Blepharospasm Study Team. Efficacy and safety of a new Botulinum Toxin Type A free of complexing proteins in the treatment of blepharospasm. J Neural Transm (Vienna). 2006; 113(3): 303–312.
    CrossRefPubMed
  15. Saad J, Gourdeau A. A direct comparison of onabotulinumtoxina (Botox) and IncobotulinumtoxinA (Xeomin) in the treatment of benign essential blepharospasm: a split-face technique. J Neuroophthalmol. 2014; 34(3): 233–236.
    CrossRefPubMed
  16. Wabbels B, Reichel G, Fulford-Smith A, et al. Double-blind, randomised, parallel group pilot study comparing two botulinum toxin type A products for the treatment of blepharospasm. J Neural Transm (Vienna). 2011; 118(2): 233–239.
    CrossRefPubMed
  17. Chundury RV, Couch SM, Holds JB, et al. Comparison of preferences between onabotulinumtoxinA (Botox) and incobotulinumtoxinA (Xeomin) in the treatment of benign essential blepharospasm. Ophthalmic Plast Reconstr Surg. 2013; 29(3): 205–207.
    CrossRefPubMed
  18. Juarez H, Salvador S, Hernandez L, et al. et al.. Cost benefit assessment of two forms of botulinum toxin type A in different pathologies. Ann Neurol. 2011; 70: S21.
  19. Grosset DG, Tyrrell EG, Grosset KA. Switch from abobotulinumtoxinA (Dysport®) to incobotulinumtoxinA (Xeomin®) botulinum toxin formulation: a review of 257 cases. J Rehabil Med. 2015; 47(2): 183–186.
    CrossRefPubMed
  20. Kollewe K, Mohammadi B, Köhler S, et al. Blepharospasm: long-term treatment with either Botox®, Xeomin® or Dysport®. J Neural Transm (Vienna). 2015; 122(3): 427–431.
    CrossRefPubMed
  21. Jankovic J, Orman J. Botulinum A toxin for cranial-cervical dystonia: a double-blind, placebo-controlled study. Neurology. 1987; 37(4): 616–623.
    CrossRefPubMed
  22. Yoshimura DM, Aminoff MJ, Tami TA, et al. Treatment of hemifacial spasm with botulinum toxin. Muscle Nerve. 1992; 15(9): 1045–1049.
    CrossRefPubMed
  23. Girlanda P, Quartarone A, Sinicropi S, et al. Unilateral injection of botulinum toxin in blepharospasm: single fiber electromyography and blink reflex study. Mov Disord. 1996; 11(1): 27–31.
    CrossRefPubMed
  24. Truong D, Comella C, Fernandez HH, et al. Dysport Benign Essential Blepharospasm Study Group. Efficacy and safety of purified botulinum toxin type A (Dysport) for the treatment of benign essential blepharospasm: a randomized, placebo-controlled, phase II trial. Parkinsonism Relat Disord. 2008; 14(5): 407–414.
    CrossRefPubMed
  25. Jankovic J, Comella C, Hanschmann A, et al. Efficacy and safety of incobotulinumtoxinA (NT 201, Xeomin) in the treatment of blepharospasm-a randomized trial. Mov Disord. 2011; 26(8): 1521–1528.
    CrossRefPubMed
  26. Odergren T, Hjaltason H, Kaakkola S, et al. A double blind, randomised, parallel group study to investigate the dose equivalence of Dysport and Botox in the treatment of cervical dystonia. J Neurol Neurosurg Psychiatry. 1998; 64(1): 6–12.
    CrossRefPubMed
  27. Ranoux D, Gury C, Fondarai J, et al. Respective potencies of Botox and Dysport: a double blind, randomised, crossover study in cervical dystonia. J Neurol Neurosurg Psychiatry. 2002; 72(4): 459–462.
    CrossRefPubMed
  28. Rystedt A, Zetterberg L, Burman J, et al. A Comparison of Botox 100 U/mL and Dysport 100 U/mL Using Dose Conversion Ratio 1: 3 and 1: 1.7 in the Treatment of Cervical Dystonia: A Double-Blind, Randomized, Crossover Trial. Clin Neuropharmacol. 2015; 38(5): 170–176.
    CrossRefPubMed
  29. Yun JiY, Kim JW, Kim HT, et al. Dysport and Botox at a ratio of 2.5:1 units in cervical dystonia: a double-blind, randomized study. Mov Disord. 2015; 30(2): 206–213.
    CrossRefPubMed
  30. Benecke R, Jost WH, Kanovsky P, et al. A new botulinum toxin type A free of complexing proteins for treatment of cervical dystonia. Neurology. 2005; 64(11): 1949–1951.
    CrossRefPubMed
  31. Lorentz IT, Subramaniam SS, Yiannikas C. Treatment of idiopathic spasmodic torticollis with botulinum toxin A: a double-blind study on twenty-three patients. Mov Disord. 1991; 6(2): 145–150.
    CrossRefPubMed
  32. Moore AP, Blumhardt LD. A double blind trial of botulinum toxin "A" in torticollis, with one year follow up. J Neurol Neurosurg Psychiatry. 1991; 54(9): 813–816.
    CrossRefPubMed
  33. Lu CS, Chen RS, Tsai CH. Double-blind, placebo-controlled study of botulinum toxin injections in the treatment of cervical dystonia. J Formos Med Assoc. 1995; 94(4): 189–192.
    PubMed
  34. Poewe W, Deuschl G, Nebe A, et al. What is the optimal dose of botulinum toxin A in the treatment of cervical dystonia? Results of a double blind, placebo controlled, dose ranging study using Dysport. German Dystonia Study Group. J Neurol Neurosurg Psychiatry. 1998; 64(1): 13–17.
    CrossRefPubMed
  35. Truong D, Duane DD, Jankovic J, et al. Efficacy and safety of botulinum type A toxin (Dysport) in cervical dystonia: results of the first US randomized, double-blind, placebo-controlled study. Mov Disord. 2005; 20(7): 783–791.
    CrossRefPubMed
  36. Comella CL, Jankovic J, Truong DD, et al. U.S. XEOMIN Cervical Dystonia Study Group. Efficacy and safety of incobotulinumtoxinA (NT 201, XEOMIN®, botulinum neurotoxin type A, without accessory proteins) in patients with cervical dystonia. J Neurol Sci. 2011; 308(1-2): 103–109.
    CrossRefPubMed
  37. Charles D, Brashear A, Hauser RA, et al. CD 140 Study Group. Efficacy, tolerability, and immunogenicity of onabotulinumtoxina in a randomized, double-blind, placebo-controlled trial for cervical dystonia. Clin Neuropharmacol. 2012; 35(5): 208–214.
    CrossRefPubMed
  38. Evidente VG, Fernandez HH, LeDoux MS, et al. A randomized, double-blind study of repeated incobotulinumtoxinA (Xeomin(®)) in cervical dystonia. J Neural Transm (Vienna). 2013; 120(12): 1699–1707.
    CrossRefPubMed
  39. Tyślerowicz M, Kiedrzyńska W, Adamkiewicz B, et al. Cervical dystonia - improving the effectiveness of botulinum toxin therapy. Neurol Neurochir Pol. 2020; 54(3): 232–242.
    CrossRefPubMed
  40. Jost WH, Biering-Sørensen Bo, Drużdż A, et al. Preferred muscles in cervical dystonia. Neurol Neurochir Pol. 2020; 54(3): 277–279.
    CrossRefPubMed
  41. Jost WH, Tatu L, Pandey S, et al. Frequency of different subtypes of cervical dystonia: a prospective multicenter study according to Col-Cap concept. J Neural Transm (Vienna). 2020; 127(1): 45–50.
    CrossRefPubMed
  42. Jost WH, Drużdż A, Pandey S, et al. Dose per muscle in cervical dystonia: pooled data from seven movement disorder centres. Neurol Neurochir Pol. 2021 [Epub ahead of print].
    CrossRefPubMed
  43. Schinwelski MJ, Sitek EJ, Wąż P, et al. Prevalence and predictors of post-stroke spasticity and its impact on daily living and quality of life. Neurol Neurochir Pol. 2019; 53(6): 449–457.
    CrossRefPubMed
  44. Sarzyńska-Długosz I, Szczepańska-Szerej A, Drużdż A, et al. Real-world effectiveness of abobotulinumtoxinA (Dysport®) in adults with upper limb spasticity in routine clinical practice: an observational study. Neurol Neurochir Pol. 2020; 54(1): 90–99.
    CrossRefPubMed
  45. Bakheit AM, Pittock S, Moore AP, et al. A randomized, double-blind, placebo-controlled study of the efficacy and safety of botulinum toxin type A in upper limb spasticity in patients with stroke. Eur J Neurol. 2001; 8(6): 559–565.
    CrossRefPubMed
  46. Brashear A, Gordon MF, Elovic E, et al. Botox Post-Stroke Spasticity Study Group. Intramuscular injection of botulinum toxin for the treatment of wrist and finger spasticity after a stroke. N Engl J Med. 2002; 347(6): 395–400.
    CrossRefPubMed
  47. Childers MK, Brashear A, Jozefczyk P, et al. Dose-dependent response to intramuscular botulinum toxin type A for upper-limb spasticity in patients after a stroke. Arch Phys Med Rehabil. 2004; 85(7): 1063–1069.
    CrossRefPubMed
  48. McCrory P, Turner-Stokes L, Baguley IJ, et al. Botulinum toxin A for treatment of upper limb spasticity following stroke: a multi-centre randomized placebo-controlled study of the effects on quality of life and other person-centred outcomes. J Rehabil Med. 2009; 41(7): 536–544.
    CrossRefPubMed
  49. Kanovský P, Slawek J, Denes Z, et al. Efficacy and safety of botulinum neurotoxin NT 201 in poststroke upper limb spasticity. Clin Neuropharmacol. 2009; 32(5): 259–265.
    CrossRefPubMed
  50. Kaji R, Osako Y, Suyama K, et al. GSK1358820 Spasticity Study Group. Botulinum toxin type A in post-stroke upper limb spasticity. Curr Med Res Opin. 2010; 26(8): 1983–1992.
    CrossRefPubMed
  51. Wolf SL, Milton SB, Reiss A, et al. Further assessment to determine the additive effect of botulinum toxin type A on an upper extremity exercise program to enhance function among individuals with chronic stroke but extensor capability. Arch Phys Med Rehabil. 2012; 93(4): 578–587.
    CrossRefPubMed
  52. Marciniak CM, Harvey RL, Gagnon CM, et al. Does botulinum toxin type A decrease pain and lessen disability in hemiplegic survivors of stroke with shoulder pain and spasticity?: a randomized, double-blind, placebo-controlled trial. Am J Phys Med Rehabil. 2012; 91(12): 1007–1019.
    CrossRefPubMed
  53. Rosales RL, Kong KHe, Goh KJ, et al. Botulinum toxin injection for hypertonicity of the upper extremity within 12 weeks after stroke: a randomized controlled trial. Neurorehabil Neural Repair. 2012; 26(7): 812–821.
    CrossRefPubMed
  54. Gracies JM, Brashear A, Jech R, et al. Safety and efficacy of abobotulinumtoxinA for hemiparesis in adults with upper limb spasticity after stroke or traumatic brain injury: a double-blind randomised controlled trial. The Lancet Neurology. 2015; 14(10): 992–1001.
    CrossRef
  55. Kaňovský P, Elovic EP, Munin MC, et al. Randomized, placebo-controlled trial of incobotulinumtoxina for upper-limb post-stroke spasticity. Muscle Nerve. 2016; 53(3): 415–421.
    CrossRefPubMed
  56. Rosales R, Balcaitiene J, Berard H, et al. Early AbobotulinumtoxinA (Dysport®) in Post-Stroke Adult Upper Limb Spasticity: ONTIME Pilot Study. Toxins. 2018; 10(7): 253.
    CrossRef
  57. Abo M, Shigematsu T, Hara H, et al. Efficacy and Safety of OnabotulinumtoxinA 400 Units in Patients with Post-Stroke Upper Limb Spasticity: Final Report of a Randomized, Double-Blind, Placebo-Controlled Trial with an Open-Label Extension Phase. Toxins (Basel). 2020; 12(2).
    CrossRefPubMed
  58. Lindsay C, Ispoglou S, Helliwell B, et al. Can the early use of botulinum toxin in post stroke spasticity reduce contracture development? A randomised controlled trial. Clin Rehabil. 2020 [Epub ahead of print]: 269215520963855.
    CrossRefPubMed
  59. Intiso D, Simone V, Bartolo M, et al. High Dosage of Botulinum Toxin Type A in Adult Subjects with Spasticity Following Acquired Central Nervous System Damage: Where Are We at? Toxins (Basel). 2020; 12(5).
    CrossRefPubMed
  60. Wissel J, Bensmail D, Ferreira JJ, et al. TOWER study investigators. Safety and efficacy of incobotulinumtoxinA doses up to 800 U in limb spasticity: The TOWER study. Neurology. 2017; 88(14): 1321–1328.
    CrossRefPubMed
  61. Wohlfarth K, Schwandt I, Wegner F, et al. Biological activity of two botulinum toxin type A complexes (Dysport and Botox) in volunteers: a double-blind, randomized, dose-ranging study. J Neurol. 2008; 255(12): 1932–1939.
    CrossRefPubMed
  62. Wein T, Esquenazi A, Jost WH, et al. OnabotulinumtoxinA for the Treatment of Poststroke Distal Lower Limb Spasticity: A Randomized Trial. PM R. 2018; 10(7): 693–703.
    CrossRefPubMed
  63. Gracies JM, Esquenazi A, Brashear A, et al. International AbobotulinumtoxinA Adult Lower Limb Spasticity Study Group. Efficacy and safety of abobotulinumtoxinA in spastic lower limb: Randomized trial and extension. Neurology. 2017; 89(22): 2245–2253.
    CrossRefPubMed
  64. Pittock SJ, Moore AP, Hardiman O, et al. A double-blind randomised placebo-controlled evaluation of three doses of botulinum toxin type A (Dysport) in the treatment of spastic equinovarus deformity after stroke. Cerebrovasc Dis. 2003; 15(4): 289–300.
    CrossRefPubMed
  65. Kaji R, Osako Y, Suyama K, et al. GSK1358820 Spasticity Study Group. Botulinum toxin type A in post-stroke lower limb spasticity: a multicenter, double-blind, placebo-controlled trial. J Neurol. 2010; 257(8): 1330–1337.
    CrossRefPubMed
  66. Burbaud P, Wiart L, Dubos JL, et al. A randomised, double blind, placebo controlled trial of botulinum toxin in the treatment of spastic foot in hemiparetic patients. J Neurol Neurosurg Psychiatry. 1996; 61(3): 265–269.
    CrossRefPubMed
  67. Dunne JW, Gracies JM, Hayes M, et al. Multicentre Study Group. A prospective, multicentre, randomized, double-blind, placebo-controlled trial of onabotulinumtoxinA to treat plantarflexor/invertor overactivity after stroke. Clin Rehabil. 2012; 26(9): 787–797.
    CrossRefPubMed
  68. Mancini F, Sandrini G, Moglia A, et al. A randomised, double-blind, dose-ranging study to evaluate efficacy and safety of three doses of botulinum toxin type A (Botox) for the treatment of spastic foot. Neurol Sci. 2005; 26(1): 26–31.
    CrossRefPubMed
  69. Picelli A, Tamburin S, Bonetti P, et al. Botulinum toxin type A injection into the gastrocnemius muscle for spastic equinus in adults with stroke: a randomized controlled trial comparing manual needle placement, electrical stimulation and ultrasonography-guided injection techniques. Am J Phys Med Rehabil. 2012; 91(11): 957–964.
    CrossRefPubMed
  70. Fietzek UM, Kossmehl P, Schelosky L, et al. Early botulinum toxin treatment for spastic pes equinovarus--a randomized double-blind placebo-controlled study. Eur J Neurol. 2014; 21(8): 1089–1095.
    CrossRefPubMed
  71. Santamato A, Micello MF, Panza F, et al. Safety and efficacy of incobotulinum toxin type A (NT 201-Xeomin) for the treatment of post-stroke lower limb spasticity: a prospective open-label study. Eur J Phys Rehabil Med. 2013; 49(4): 483–489.
    PubMed
  72. Brin MF, James C, Maltman J. Botulinum toxin type A products are not interchangeable: a review of the evidence. Biologics. 2014; 8: 227–241.
    CrossRefPubMed
  73. Spiegel LL, Ostrem JL, Bledsoe IO. FDA Approvals and Consensus Guidelines for Botulinum Toxins in the Treatment of Dystonia. Toxins (Basel). 2020; 12(5).
    CrossRefPubMed
  74. Simpson DM, Blitzer A, Brashear A, et al. So Y; Therapeutics and Technology Assessment Subcommittee of the American Academy of . Practice guideline update summary: Botulinum neurotoxin for the treatment of blepharospasm, cervical dystonia, adult spasticity, and headache: Report of the Guideline Development Subcommittee of the American Academy of . Neurology. 2008; 70: 1699–706.
  75. Albanese A, Asmus F, Bhatia KP, et al. EFNS guidelines on diagnosis and treatment of primary dystonias. Eur J Neurol. 2011; 18(1): 5–18.
    CrossRefPubMed
  76. Simpson DM, Hallett M, Ashman EJ, et al. Practice guideline update summary: Botulinum neurotoxin for the treatment of blepharospasm, cervical dystonia, adult spasticity, and headache: Report of the Guideline Development Subcommittee of the American Academy of Neurology. Neurology. 2016; 86(19): 1818–1826.
    CrossRefPubMed
  77. Wissel J, Ward AB, Erztgaard P, et al. European consensus table on the use of botulinum toxin type A in adult spasticity. J Rehabil Med. 2009; 41(1): 13–25.
    CrossRefPubMed
  78. Aoki KR, Ranoux D, Wissel J. Using translational medicine to understand clinical differences between botulinum toxin formulations. Eur J Neurol. 2006; 13 Suppl 4: 10–19.
    CrossRefPubMed
  79. Simpson DM, Gracies JM, Graham HK, et al. Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. Assessment: Botulinum neurotoxin for the treatment of spasticity (an evidence-based review): report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. Neurology. 2008; 70(19): 1691–1698.
    CrossRefPubMed
  80. Hefter H, Hartmann CJ, Kahlen U, et al. Clinical Improvement After Treatment With IncobotulinumtoxinA (XEOMIN®) in Patients With Cervical Dystonia Resistant to Botulinum Toxin Preparations Containing Complexing Proteins. Front Neurol. 2021; 12: 636590.
    CrossRefPubMed

Regulations

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

By VM Media Group sp. z o.o., ul. Świętokrzyska 73, 80–180 Gdańsk, Poland
tel.:+48 58 320 94 94, fax:+48 58 320 94 60, e-mail: viamedica@viamedica.pl